NOVAVAX INC (NVAX) Stock Overview
USA - NASDAQ:NVAX - US6700024010 - Common Stock
NVAX Key Statistics, Chart & Performance
The current stock price of NVAX is 7.98 USD. In the past month the price decreased by -15.38%. In the past year, price decreased by -41.37%.
NVAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.62 | 385.71B | ||
| AMGN | AMGEN INC | 12.67 | 148.80B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 142.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 101.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 59.35B | ||
| ARGX | ARGENX SE - ADR | 81.59 | 46.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.67 | 38.56B | ||
| INSM | INSMED INC | N/A | 30.85B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.26B | ||
| NTRA | NATERA INC | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About NVAX
Company Profile
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The company is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. The company provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Company Info
NOVAVAX INC
700 Quince Orchard Road
Gaithersburg MARYLAND 20878 US
CEO: Stanley C. Erck
Employees: 952
Phone: 12402682000
NOVAVAX INC / NVAX FAQ
What is the stock price of NOVAVAX INC today?
The current stock price of NVAX is 7.98 USD. The price decreased by -3.62% in the last trading session.
What is the ticker symbol for NOVAVAX INC stock?
The exchange symbol of NOVAVAX INC is NVAX and it is listed on the Nasdaq exchange.
On which exchange is NVAX stock listed?
NVAX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NOVAVAX INC stock?
14 analysts have analysed NVAX and the average price target is 13.55 USD. This implies a price increase of 69.82% is expected in the next year compared to the current price of 7.98. Check the NOVAVAX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NOVAVAX INC worth?
NOVAVAX INC (NVAX) has a market capitalization of 1.30B USD. This makes NVAX a Small Cap stock.
How many employees does NOVAVAX INC have?
NOVAVAX INC (NVAX) currently has 952 employees.
What are the support and resistance levels for NOVAVAX INC (NVAX) stock?
NOVAVAX INC (NVAX) has a support level at 7.67 and a resistance level at 8.29. Check the full technical report for a detailed analysis of NVAX support and resistance levels.
Is NOVAVAX INC (NVAX) expected to grow?
The Revenue of NOVAVAX INC (NVAX) is expected to grow by 57.02% in the next year. Check the estimates tab for more information on the NVAX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NOVAVAX INC (NVAX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVAX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVAX, evaluating the profitability, health, valuation and growth aspects
- NOVAVAX INC (NVAX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NOVAVAX INC (NVAX) Sales and EPS estimates to see what analysts future expectations are.
- NOVAVAX INC (NVAX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NOVAVAX INC (NVAX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NOVAVAX INC (NVAX) Stock Chart to make your own analysis
- NOVAVAX INC (NVAX) Latest news and press-releases to stay up to date.
Does NOVAVAX INC (NVAX) stock pay dividends?
NVAX does not pay a dividend.
When does NOVAVAX INC (NVAX) report earnings?
NOVAVAX INC (NVAX) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of NOVAVAX INC (NVAX)?
The PE ratio for NOVAVAX INC (NVAX) is 4.07. This is based on the reported non-GAAP earnings per share of 1.96 and the current share price of 7.98 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVAX.
What is the Short Interest ratio of NOVAVAX INC (NVAX) stock?
The outstanding short interest for NOVAVAX INC (NVAX) is 25.71% of its float. Check the ownership tab for more information on the NVAX short interest.
NVAX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NVAX. When comparing the yearly performance of all stocks, NVAX is a bad performer in the overall market: 86% of all stocks are doing better.
NVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NVAX. While NVAX is still in line with the averages on profitability rating, there are concerns on its financial health.
NVAX Financial Highlights
Over the last trailing twelve months NVAX reported a non-GAAP Earnings per Share(EPS) of 1.96. The EPS increased by 171.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 39.2% | ||
| ROA | 31.64% | ||
| ROE | 1123.78% | ||
| Debt/Equity | 5.93 |
NVAX Forecast & Estimates
14 analysts have analysed NVAX and the average price target is 13.55 USD. This implies a price increase of 69.82% is expected in the next year compared to the current price of 7.98.
For the next year, analysts expect an EPS growth of 239.6% and a revenue growth 57.02% for NVAX